A Phase 1/2 interventional study of Acetylcysteine and EH301 in Amyotrophic Lateral Sclerosis, sponsored by Biogipuzkoa Health Research Institute. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Biogipuzkoa Health Research Institute · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 32nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 6 of the 15 other live ones, and was the 52nd registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Prilenia · Sites in Spain, United States, Belgium and 10 more countries
Ages 18–80
PhenoNet, Inc. · Sites in Spain, United States, Czechia and 3 more countries
Ages 18–75
Zydus Therapeutics Inc. · Sites in Spain, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 24
First in 2007; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 227 across the 51 interventional studies, 60 across the 5 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 56 have an industry lead sponsor. The 10 most frequent:
Biogipuzkoa Health Research Institute is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Biogipuzkoa Health Research Institute has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Amyotrophic Lateral Sclerosis with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07414212Biogipuzkoa Health Research InstituteEvaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) | 2026-11-25 |
| NCT07142291PhenoNet, Inc.PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | 2027-03 |
| NCT07100119Eli Lilly and CompanyA Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate whether a combination of N-acetylcysteine (NAC) and EH-301 can slow down or improve symptoms of amyotrophic lateral sclerosis (ALS). Researchers will assess changes in disease progression using the ALS Functional Rating Scale-Revised (ALSFRS-R), a standard tool for measuring daily functioning in people with ALS.
The main question is whether taking NAC together with EH-301 can prevent symptom worsening and possibly improve existing ALS symptoms.
Participants will be randomly assigned to receive either the active combination (NAC + EH-301) or matching placebos for 6 months. During this period, they will attend regular clinic visits for evaluations, tests, and safety monitoring.
After completing the initial 6-month phase, all participants may choose to join a 6-month open-label extension, where everyone receives the active treatment regardless of their original group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Acceptance by women to use at least one highly effective method of during the study 30 days prior to taking the nutraceutical and drug and throughout the study. The following are considered highly effective contraceptive methods:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination of 600 mg of NAC + 1800 mg of EH301 (1500 mg of NR + 300 mg of PTER) + 100 mg of Riluzole (standard treatment for both arms)
Drug: Acetylcysteine · Dietary Supplement: EH301 · Drug: Riluzole
Combination of NAC placebo + EH301 placebo + 100 mg of Riluzole (standard treatment for both arms)
Drug: Riluzole
Daily dose of 600mg of effervescent powder
Also known as: NAC
Drug pages: Nicotinamide-beta-ribosideStudies of Nicotinamide-beta-ribosideNicotinamide-beta-riboside pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PterostilbeneStudies of PterostilbenePterostilbene pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Daily dose of 1800mg of capsules
Also known as: Nicotinamide riboside and pterostilbene
Daily dose of 100mg of tablets
ALSFRS-R scale
Change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) \[range from 0 to 48, being 48 normal function and 0 complete function loss\] to assess disease progression and evaluate the clinical efficacy and safety of the combination of NAC and EH301 during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.
Time frame: Up to 48 weeks
Muscle strength
Muscle strength measured by hand dynamometry during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.
Time frame: Up to 48 weeks
Ventilation-free survival
Percentage of participants who remain alive without requiring tracheotomy or permanent invasive ventilation during the randomized period (24 weeks) or, for those who enter the open-label extension, up to 48 weeks.
Time frame: Up to 48 weeks
Quality of life (ALSAQ-40)
Quality of life assessed using the ALSAQ-40 questionnaire \[range from 0 to 100, being 0 best health status and 100 worst health status\] during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.
Time frame: Up to 48 weeks
Respiratory function (%FVC)
Respiratory function measured as percent predicted forced vital capacity (%FVC) during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.
Time frame: Up to 48 weeks
Time to gastrostomy
Time from baseline to placement of gastrostomy tube (percutaneous endoscopic gastrostomy or radiologically inserted gastrostomy). Participants in the open-label extension are followed for events up to 48 weeks.
Time frame: Up to 48 weeks
Combined Assessment of Function and Survival (CAFS)
Combined Assessment of Function and Survival (CAFS) score calculated using ALSFRS-R change and survival status \[no fixed numerical range; ranking score where higher values indicate better combined functional status and survival\] during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.
Time frame: Up to 48 weeks
Neurofilament light chain (NfL) biomarker
Neurofilament light chain (NfL) levels in serum and cerebrospinal fluid will be measured for biomarker assessment. Analyses will evaluate the change from baseline in NfL concentrations during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.
Time frame: Up to 48 weeks
Serum lipidomic profile
Serum lipidomic components will be measured for biomarker assessment. Analyses will evaluate the change from baseline in the serum lipidomic profile during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.
Time frame: Up to 48 weeks
Plan to share: No
Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.
Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nicotinamide-beta-riboside · Pterostilbene
Amyotrophic Lateral Sclerosis →
Biogipuzkoa Health Research Institute